TAMRA DILLON: Open Payments
NPI 1497378657 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 18 payments from 6 companies in 2025. Trend: 2023 $1,082 · 2024 $1,056 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 12 | $531 |
| E.R. Squibb & Sons, L.L.C. | 1 | $90 |
| Alkermes, Inc. | 2 | $39 |
| ABBVIE INC. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: Auvelity, COBENFY, ARISTADA, VRAYLAR, CAPLYTA, TRINTELLIX.
Industry payments across WA — which companies pay providers there.
